{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Koenig W"],"funding":["Novartis Pharma AG","Novartis"],"pubmed_abstract":["Patients with cerebrovascular disease (CeVD) have been shown to benefit from lipid-lowering therapies, but guideline-recommended levels of low-density lipoprotein cholesterol (LDL-C) are often not attained with statin treatment alone. The ORION-9, ORION-10, and ORION-11 trials evaluated the efficacy and safety of inclisiran in 3660 primary and secondary prevention patients with hyperlipidemia despite maximum tolerated statin treatment. This pooled <i>post hoc</i> analysis comprised 202 randomized patients from those trials with established CeVD who had received either 284 mg inclisiran (equivalent to 300 mg inclisiran sodium, <i>n</i> = 110) or placebo (<i>n</i> = 92) on Days 1, 90, and 6-monthly thereafter up to Day 540. At baseline, mean (SD) LDL-C was 108.4 (34.3) mg/dL and 110.5 (35.3)"],"journal":["American journal of preventive cardiology"],"pagination":["100503"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10209488"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11."],"pmcid":["PMC10209488"],"pubmed_authors":["Landmesser U","Koenig W","Raal FJ","Wright RS","Han J","Ray KK","Leiter LA","Schwartz GG","Conde LG"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11.","description":"Patients with cerebrovascular disease (CeVD) have been shown to benefit from lipid-lowering therapies, but guideline-recommended levels of low-density lipoprotein cholesterol (LDL-C) are often not attained with statin treatment alone. The ORION-9, ORION-10, and ORION-11 trials evaluated the efficacy and safety of inclisiran in 3660 primary and secondary prevention patients with hyperlipidemia despite maximum tolerated statin treatment. This pooled <i>post hoc</i> analysis comprised 202 randomized patients from those trials with established CeVD who had received either 284 mg inclisiran (equivalent to 300 mg inclisiran sodium, <i>n</i> = 110) or placebo (<i>n</i> = 92) on Days 1, 90, and 6-monthly thereafter up to Day 540. At baseline, mean (SD) LDL-C was 108.4 (34.3) mg/dL and 110.5 (35.3)","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-05-29T22:31:08.63Z","creation":"2025-02-19T04:45:34.949Z"},"accession":"S-EPMC10209488","cross_references":{"pubmed":["37252442"],"doi":["10.1016/j.ajpc.2023.100503"]}}